Paul Matthias Diderichsen

13PUBLICATIONS
37CO-AUTHORS
Molecular targetsEpidemiological modellingPharmacogenomicsRegenerative medicine (incl. stem cells)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Feb 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.

Jatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher

|Oct 24, 2025
Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis.

Yushi Kashihara, Li Qin, Shinji Shimizu

|Aug 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.

Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann

|Jul 14, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 Trial.

Abhishek G Sathe, Aksana K Jones, Paul M Diderichsen

|Jun 05, 2025
Use of PopPK and E-R Analyses toward Explaining Causal Link Between ADAMTS13 in Recombinant vs. Plasma-Based Therapies and Clinical Effects in cTTP.

Munjal Patel, Huijuan Xu, Olivier Barriere

|Mar 03, 2025
Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study.

Michael J Hanley, Thomas R Larson, Paul M Diderichsen

Pageof 3

Frequent Collaborators

4 joint publications

Michael J Hanley

4 joint publications

Karthik Venkatakrishnan

4 joint publications

Neeraj Gupta

2 joint publications

Timothy A Yap